1. Home
  2. JAGU vs HBIO Comparison

JAGU vs HBIO Comparison

Compare JAGU & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Uranium Corp. Class A Common Shares

JAGU

Jaguar Uranium Corp. Class A Common Shares

N/A

Current Price

$1.60

Market Cap

32.3M

Sector

N/A

ML Signal

N/A

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$8.11

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGU
HBIO
Founded
2022
1901
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
32.3M
26.5M
IPO Year
2025
2000

Fundamental Metrics

Financial Performance
Metric
JAGU
HBIO
Price
$1.60
$8.11
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
87.3K
20.3K
Earning Date
03-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
68.67
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.41
$0.38
52 Week High
$3.60
$8.12

Technical Indicators

Market Signals
Indicator
JAGU
HBIO
Relative Strength Index (RSI) 45.26 76.83
Support Level $1.46 $5.91
Resistance Level $1.78 N/A
Average True Range (ATR) 0.12 0.31
MACD 0.01 0.10
Stochastic Oscillator 36.00 90.37

Price Performance

Historical Comparison
JAGU
HBIO

About JAGU Jaguar Uranium Corp. Class A Common Shares

Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: